Overview

Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This trial is designed to quantify the pharmacodynamic (PD) and pharmacokinetic (PK) interaction(s) between an anaesthetic drug (remimazolam) and an opioid (remifentanil). Remimazolam is a new anaesthetic drug with a sedative effect, which, in combination with an opioid can be used to achieve general anaesthesia. To date, however, no clinical trials have been conducted to specifically assess the potential for drug-drug interactions between remimazolam and remifentanil. Greater understanding of the potential for such interactions will help define more appropriate dosing regimens with less over-sedation and associated side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Paion UK Ltd.
Collaborators:
QPS
University Medical Center Groningen
Treatments:
Remifentanil